ADD-ON therapy for the symptomatic treatment of stable angina pectoris, Menarini's Ranexa (ranolazine) has been the only new chemical entity (NCE) added to the ARTG by the Therapeutic Goods Administration in October.
The drug is indicated for angina pectoris patients taking maximum tolerated doses of a beta-blocker or a calcium channel blocker but have inadequate symptom control.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Oct 17
